Diagnosis and management of disseminated XXXX .

@entity1 @entity548 @entity39 @entity409 @entity1003 @entity3459 @entity5642 @entity929 @entity930 @entity751 @entity715 @entity288
@entity5642 ( @entity751 , @entity1003 ) is a syndrome which may complicate a number of pathologic states. If clotting factors and platelets are "consumed" more rapidly than the @entity1 can produce them, they may fall to levels which are not adequate for hemostasis. Thus, @entity715 with resulting @entity39 and @entity548 may occur simultaneously in the same @entity1 . Local fibrinolysis (secondary fibrinolysis) may remove or partially remove intravascular thrombi, thus protecting against local tissue @entity39 . Diagnosis of the fulminating syndrome is usually simple and depends upon a few relatively easy tests. If the syndrome is low grade, diagnosis is very difficult and may be impossible without sophisticated techniques. Differential diagnosis from @entity3459 secondary to @entity409 is extremely difficult. Treatment in the fulminating case before intravascular thrombi can cause irreversible tissue damage is urgent. Treatment depends upon therapy of the underlying disease plus adequate heparinization. It may be necessary to administer platelets and blood fractions after heparinization. @entity288 are not contraindicated, particularly when the @entity1 is heparinized. @entity929 ( @entity930 , Amicar) is contraindicated. This drug inhibits local fibrinolysis, which is protective to the @entity1 .
